Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Discovery Medicine
|
April 29, 2010
The therapeutic potential of microRNA modulation
Aimee Jackson, Peter S Linsley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2021
Reply to G. Gui et al
Charles Craddock, Aimee Jackson, Sylvie D Freeman
BMC Cancer
|
July 12, 2021
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)
Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell, et al.
BMC Cancer
|
May 22, 2019
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease
Niamh Appleby, Toby A Eyre, Maite Cabes, et al.
British Journal of Haematology
|
April 29, 2020
De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromes
Sally Killick, Aimee Jackson, Helen C Coulthard, et al.
BMC Medical Research Methodology
|
May 3, 2025
The REFRACT trial: implementation of Bayesian power priors in a randomised, sequential phase II adaptive platform trial
Charlotte Gaskell, Kim Linton, Mark Bishton, et al.
BMJ Open
|
June 1, 2023
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission
David I Marks, Anna Castleton, Eduardo Olavarria, et al.
BMC Cancer
|
January 9, 2025
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
Graham McIlroy, Charlotte Gaskell, Aimee Jackson, et al.
British Journal of Haematology
|
September 7, 2021
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
Justin Loke, Marlen Metzner, Rebecca Boucher, et al.
Bone Marrow Transplantation
|
August 27, 2021
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial
Ram Malladi, Ikhlaaq Ahmed, Graham McIlroy, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Discovery Medicine
|
April 29, 2010
The therapeutic potential of microRNA modulation
Aimee Jackson, Peter S Linsley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2021
Reply to G. Gui et al
Charles Craddock, Aimee Jackson, Sylvie D Freeman
BMC Cancer
|
July 12, 2021
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)
Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell, et al.
BMC Cancer
|
May 22, 2019
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease
Niamh Appleby, Toby A Eyre, Maite Cabes, et al.
British Journal of Haematology
|
April 29, 2020
De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromes
Sally Killick, Aimee Jackson, Helen C Coulthard, et al.
BMC Medical Research Methodology
|
May 3, 2025
The REFRACT trial: implementation of Bayesian power priors in a randomised, sequential phase II adaptive platform trial
Charlotte Gaskell, Kim Linton, Mark Bishton, et al.
BMJ Open
|
June 1, 2023
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission
David I Marks, Anna Castleton, Eduardo Olavarria, et al.
BMC Cancer
|
January 9, 2025
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
Graham McIlroy, Charlotte Gaskell, Aimee Jackson, et al.
British Journal of Haematology
|
September 7, 2021
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
Justin Loke, Marlen Metzner, Rebecca Boucher, et al.
Bone Marrow Transplantation
|
August 27, 2021
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial
Ram Malladi, Ikhlaaq Ahmed, Graham McIlroy, et al.
Page
of 3